#Hong Kong #Pulnovo Medical #Qiming Venture #EQT Group

Pulnovo Medical Welcomes New Investor EQT

Pulnovo Medical, recognized globally for its pioneering medical devices in treating pulmonary hypertension (PH) and heart failure (HF), has recently welcomed the EQT Group as a new investor. This collaboration follows the company's successful CE-MDR certification, marking a significant milestone in its mission to address pressing clinical needs worldwide.

Founded in 2013, Pulnovo Medical has made substantial advances in developing its flagship cardiovascular device based on the innovative Pulmonary Artery Denervation (PADN) technology. This breakthrough approach meets a considerable unmet need within cardiovascular care, offering new hope and opportunities for patients suffering from these debilitating conditions.

Pulnovo's devices were first recognized by the U.S. FDA as a breakthrough device in 2021 and received humanitarian use designation in 2023. The company has also secured approvals from Chinese regulatory authorities, further affirming its commitment to producing effective solutions for pulmonary-related diseases. Most recently, the CE-MDR certification in March 2025 has set the stage for Pulnovo's international expansion.

Zoe Zhu, a Director at EQT Private Capital Asia, emphasized the critical global need for effective treatments in pulmonary hypertension and heart failure. She noted, “The PADN solution provides renewed hope for patients, bolstered by robust clinical evidence and a growing backing from the medical community. EQT is excited to leverage our expertise in healthcare and biosciences, combined with our extensive global network, to help Pulnovo deliver innovative cardiovascular solutions.